Sugemalimab retains binding affinity to Fcγ receptor I and thus can effectively induce antibody-dependent cellular phagocytosis through cross-linking of PD-L1-positive tumor cells with macrophages prevalent in the tumor microenvironment and may further enhance tumor antigen presentation (50). The gene discussed is CD274; the disease is neoplasm.